{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:13Z","timestamp":1792788253916,"version":"4.5.0"},"reference-count":311,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82070118"],"award-info":[{"award-number":["82070118"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China","award":["82570191"],"award-info":[{"award-number":["82570191"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Young Scientists Project of the National Key Research and Development Program of China","award":["2025YFC3511400"],"award-info":[{"award-number":["2025YFC3511400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-01003-0","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:23:59Z","timestamp":1790699039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications"],"prefix":"10.1186","volume":"14","author":[{"given":"Jiansong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiudi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"4","key":"1003_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"17","key":"1003_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"1003_CR3","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162\u20138.","journal-title":"Blood"},{"issue":"7","key":"1003_CR4","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.","journal-title":"PLoS Med"},{"issue":"25","key":"1003_CR5","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"25","key":"1003_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"issue":"20","key":"1003_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"7","key":"1003_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"11","key":"1003_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"3","key":"1003_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","volume":"78","author":"B Psaila","year":"2020","unstructured":"Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, et al. Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets. Mol Cell. 2020;78(3):477\u201392. e8.","journal-title":"Mol Cell"},{"issue":"4","key":"1003_CR11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3324\/haematol.2024.285598","volume":"110","author":"SH Jung","year":"2025","unstructured":"Jung SH, Lee SE, Yun S, Min DE, Shin Y, Chung YJ, et al. Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis. Haematologica. 2025;110(4):938\u201351.","journal-title":"Haematologica"},{"issue":"12","key":"1003_CR12","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1172\/JCI26891","volume":"115","author":"SR Patel","year":"2005","unstructured":"Patel SR, Hartwig JH, Italiano JE. Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115(12):3348\u201354.","journal-title":"J Clin Invest"},{"issue":"10","key":"1003_CR13","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1182\/blood-2005-07-2755","volume":"107","author":"H Schulze","year":"2006","unstructured":"Schulze H, Korpal M, Hurov J, Kim SW, Zhang J, Cantley LC, et al. Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood. 2006;107(10):3868\u201375.","journal-title":"Blood"},{"issue":"6","key":"1003_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1083\/jcb.201304054","volume":"201","author":"KR Machlus","year":"2013","unstructured":"Machlus KR, Italiano JE Jr. The incredible journey: From megakaryocyte development to platelet formation. J Cell Biol. 2013;201(6):785\u201396.","journal-title":"J Cell Biol"},{"issue":"6","key":"1003_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2013-03-492330","volume":"123","author":"A Eckly","year":"2014","unstructured":"Eckly A, Heijnen H, Pertuy F, Geerts W, Proamer F, Rinckel JY, et al. Biogenesis of the demarcation membrane system (DMS) in megakaryocytes. Blood. 2014;123(6):921\u201330.","journal-title":"Blood"},{"issue":"3","key":"1003_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/blood.2023020895","volume":"143","author":"NL Asquith","year":"2024","unstructured":"Asquith NL, Carminita E, Camacho V, Rodriguez-Romera A, Stegner D, Freire D, et al. The bone marrow is the primary site of thrombopoiesis. Blood. 2024;143(3):272\u20138.","journal-title":"Blood"},{"issue":"6","key":"1003_CR17","doi-asserted-by":"publisher","first-page":"240041","DOI":"10.1098\/rsob.240041","volume":"14","author":"H Liu","year":"2024","unstructured":"Liu H, Welburn JPI. A circle of life: platelet and megakaryocyte cytoskeleton dynamics in health and disease. Open Biol. 2024;14(6):240041.","journal-title":"Open Biol"},{"issue":"3","key":"1003_CR18","doi-asserted-by":"publisher","first-page":"030503","DOI":"10.11613\/BM.2024.030503","volume":"34","author":"A Ivanovna Gabrilchak","year":"2024","unstructured":"Ivanovna Gabrilchak A, Anatolievna Gusyakova O, Aleksandrovich Antipov V, Alekseevna Medvedeva E, Leonidovna Tukshumskaya L. A modern overview of the process of platelet formation (thrombocytopoiesis) and its dependence on several factors. Biochem Med (Zagreb). 2024;34(3):030503.","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"1003_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","volume":"27","author":"G Barosi","year":"2014","unstructured":"Barosi G. Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol. 2014;27(2):129\u201340.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"1003_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Primary myelofibrosis. 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145\u201362.","journal-title":"Am J Hematol"},{"issue":"1","key":"1003_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41467-017-00201-7","volume":"8","author":"D Stegner","year":"2017","unstructured":"Stegner D, vanEeuwijk JMM, Angay O, Gorelashvili MG, Semeniak D, Pinnecker J, et al. Thrombopoiesis is spatially regulated by the bone marrow vasculature. Nat Commun. 2017;8(1):127.","journal-title":"Nat Commun"},{"key":"1003_CR22","doi-asserted-by":"publisher","first-page":"1610217","DOI":"10.3389\/pore.2022.1610217","volume":"28","author":"T Szekely","year":"2022","unstructured":"Szekely T, Krenacs T, Maros ME, Bodor C, Daubner V, Csizmadia A, et al. Correlations Between the Expression of Stromal Cell Activation Related Biomarkers, L-NGFR, Phospho-ERK1-2 and CXCL12, and Primary Myelofibrosis Progression. Pathol Oncol Res. 2022;28:1610217.","journal-title":"Pathol Oncol Res"},{"issue":"7470","key":"1003_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12495","volume":"502","author":"A Sanjuan-Pla","year":"2013","unstructured":"Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232\u20136.","journal-title":"Nature"},{"issue":"7690","key":"1003_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature25455","volume":"554","author":"J Carrelha","year":"2018","unstructured":"Carrelha J, Meng Y, Kettyle LM, Luis TC, Norfo R, Alcolea V, et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature. 2018;554(7690):106\u201311.","journal-title":"Nature"},{"issue":"8","key":"1003_CR25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/cells13080704","volume":"13","author":"BA Manso","year":"2024","unstructured":"Manso BA, Rodriguez YBA, Forsberg EC. From Hematopoietic Stem Cells to Platelets: Unifying Differentiation Pathways Identified by Lineage Tracing Mouse Models. Cells. 2024;13(8):704.","journal-title":"Cells"},{"issue":"6","key":"1003_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41590-024-01845-6","volume":"25","author":"J Carrelha","year":"2024","unstructured":"Carrelha J, Mazzi S, Winroth A, Hagemann-Jensen M, Ziegenhain C, Hogstrand K, et al. Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells. Nat Immunol. 2024;25(6):1007\u201319.","journal-title":"Nat Immunol"},{"issue":"6269","key":"1003_CR27","doi-asserted-by":"publisher","first-page":"aab2116","DOI":"10.1126\/science.aab2116","volume":"351","author":"F Notta","year":"2016","unstructured":"Notta F, Zandi S, Takayama N, Dobson S, Gan OI, Wilson G, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science. 2016;351(6269):aab2116.","journal-title":"Science"},{"issue":"8","key":"1003_CR28","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/j.celrep.2018.10.084","volume":"25","author":"YC Lu","year":"2018","unstructured":"Lu YC, Sanada C, Xavier-Ferrucio J, Wang L, Zhang PX, Grimes HL, et al. The Molecular Signature of Megakaryocyte-Erythroid Progenitors Reveals a Role for the Cell Cycle in Fate Specification. Cell Rep. 2018;25(8):2083\u201393. e4.","journal-title":"Cell Rep"},{"issue":"7","key":"1003_CR29","doi-asserted-by":"publisher","first-page":"114388","DOI":"10.1016\/j.celrep.2024.114388","volume":"43","author":"CM Garyn","year":"2024","unstructured":"Garyn CM, Bover O, Murray JW, Ma J, Salas-Briceno K, Ross SR, et al. G2 arrest primes hematopoietic stem cells for megakaryopoiesis. Cell Rep. 2024;43(7):114388.","journal-title":"Cell Rep"},{"issue":"3","key":"1003_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.immuni.2024.02.006","volume":"57","author":"JJ Li","year":"2024","unstructured":"Li JJ, Liu J, Li YE, Chen LV, Cheng H, Li Y, et al. Differentiation route determines the functional outputs of adult megakaryopoiesis. Immunity. 2024;57(3):478\u201394. e6.","journal-title":"Immunity"},{"issue":"12","key":"1003_CR31","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1016\/j.cell.2024.04.018","volume":"187","author":"DM Poscablo","year":"2024","unstructured":"Poscablo DM, Worthington AK, Smith-Berdan S, Rommel MGE, Manso BA, Adili R, et al. An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis. Cell. 2024;187(12):3090\u2013e10721.","journal-title":"Cell"},{"issue":"98","key":"1003_CR32","doi-asserted-by":"publisher","first-page":"eadk3469","DOI":"10.1126\/sciimmunol.adk3469","volume":"9","author":"M Aksoz","year":"2024","unstructured":"Aksoz M, Gafencu GA, Stoilova B, Buono M, Zhang Y, Turkalj S, et al. Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved. Sci Immunol. 2024;9(98):eadk3469.","journal-title":"Sci Immunol"},{"issue":"3","key":"1003_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.stem.2021.01.018","volume":"28","author":"J Tong","year":"2021","unstructured":"Tong J, Sun T, Ma S, Zhao Y, Ju M, Gao Y, et al. Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. Cell Stem Cell. 2021;28(3):502\u201313. e6.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"1003_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","volume":"77","author":"TD Bartley","year":"1994","unstructured":"Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77(7):1117\u201324.","journal-title":"Cell"},{"issue":"5177","key":"1003_CR35","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1126\/science.8073287","volume":"265","author":"AL Gurney","year":"1994","unstructured":"Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265(5177):1445\u20137.","journal-title":"Science"},{"issue":"6481","key":"1003_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/369533a0","volume":"369","author":"FJ de Sauvage","year":"1994","unstructured":"de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533\u20138.","journal-title":"Nature"},{"issue":"4","key":"1003_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood.V87.4.1309.bloodjournal8741309","volume":"87","author":"H Nagahisa","year":"1996","unstructured":"Nagahisa H, Nagata Y, Ohnuki T, Osada M, Nagasawa T, Abe T, et al. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood. 1996;87(4):1309\u201316.","journal-title":"Blood"},{"issue":"3","key":"1003_CR38","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2007-05-088500","volume":"111","author":"K Kaushansky","year":"2008","unstructured":"Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111(3):981\u20136.","journal-title":"Blood"},{"issue":"12","key":"1003_CR39","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI26674","volume":"115","author":"K Kaushansky","year":"2005","unstructured":"Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339\u201347.","journal-title":"J Clin Invest"},{"issue":"4","key":"1003_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12079-018-0480-4","volume":"12","author":"FA Bhat","year":"2018","unstructured":"Bhat FA, Advani J, Khan AA, Mohan S, Pal A, Gowda H, et al. A network map of thrombopoietin signaling. J Cell Commun Signal. 2018;12(4):737\u201343.","journal-title":"J Cell Commun Signal"},{"issue":"19","key":"1003_CR41","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1016\/j.cell.2023.07.037","volume":"186","author":"N Tsutsumi","year":"2023","unstructured":"Tsutsumi N, Masoumi Z, James SC, Tucker JA, Winkelmann H, Grey W, et al. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis. Cell. 2023;186(19):4189\u2013e20322.","journal-title":"Cell"},{"issue":"4","key":"1003_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/biom14040489","volume":"14","author":"K Kaushansky","year":"2024","unstructured":"Kaushansky K. Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey. Biomolecules. 2024;14(4):489.","journal-title":"Biomolecules"},{"issue":"4","key":"1003_CR43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","volume":"6","author":"S Elf","year":"2016","unstructured":"Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, et al. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016;6(4):368\u201381.","journal-title":"Cancer Discov"},{"issue":"25","key":"1003_CR44","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood.2019000622","volume":"134","author":"J How","year":"2019","unstructured":"How J, Hobbs GS, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood. 2019;134(25):2242\u20138.","journal-title":"Blood"},{"issue":"2","key":"1003_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12185-019-02800-0","volume":"111","author":"M Araki","year":"2020","unstructured":"Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. Int J Hematol. 2020;111(2):200\u20135.","journal-title":"Int J Hematol"},{"issue":"13","key":"1003_CR46","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1093\/emboj\/16.13.3965","volume":"16","author":"RA Shivdasani","year":"1997","unstructured":"Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16(13):3965\u201373.","journal-title":"EMBO J"},{"issue":"9","key":"1003_CR47","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood-2004-04-1320","volume":"105","author":"AM Vannucchi","year":"2005","unstructured":"Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood. 2005;105(9):3493\u2013501.","journal-title":"Blood"},{"issue":"17","key":"1003_CR48","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","volume":"121","author":"M Zingariello","year":"2013","unstructured":"Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D\u2019Amore E, et al. Characterization of the TGF-beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood. 2013;121(17):3345\u201363.","journal-title":"Blood"},{"issue":"13","key":"1003_CR49","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood.2024027363","volume":"146","author":"L Varricchio","year":"2025","unstructured":"Varricchio L, Mosoyan G, Elghaity-Beckley S, Mia MB, Handa S, Salib C, et al. Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression. Blood. 2025;146(13):1612\u201324.","journal-title":"Blood"},{"issue":"3","key":"1003_CR50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0002-9440(10)62056-1","volume":"167","author":"AM Vannucchi","year":"2005","unstructured":"Vannucchi AM, Pancrazzi A, Guglielmelli P, Di Lollo S, Bogani C, Baroni G, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol. 2005;167(3):849\u201358.","journal-title":"Am J Pathol"},{"issue":"4","key":"1003_CR51","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI82905","volume":"127","author":"L Gilles","year":"2017","unstructured":"Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, et al. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017;127(4):1316\u201320.","journal-title":"J Clin Invest"},{"issue":"3","key":"1003_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nm997","volume":"10","author":"M Ichikawa","year":"2004","unstructured":"Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10(3):299\u2013304.","journal-title":"Nat Med"},{"issue":"15","key":"1003_CR53","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1128\/MCB.00090-09","volume":"29","author":"H Huang","year":"2009","unstructured":"Huang H, Yu M, Akie TE, Moran TB, Woo AJ, Tu N, et al. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol. 2009;29(15):4103\u201315.","journal-title":"Mol Cell Biol"},{"issue":"23","key":"1003_CR54","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1182\/blood-2014-11-610519","volume":"125","author":"ON Kuvardina","year":"2015","unstructured":"Kuvardina ON, Herglotz J, Kolodziej S, Kohrs N, Herkt S, Wojcik B, et al. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. Blood. 2015;125(23):3570\u20139.","journal-title":"Blood"},{"issue":"11","key":"1003_CR55","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/bloodadvances.2022008591","volume":"7","author":"C Wang","year":"2023","unstructured":"Wang C, Tu Z, Cai X, Wang W, Davis AK, Nattamai K, et al. A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Adv. 2023;7(11):2590\u2013605.","journal-title":"Blood Adv"},{"issue":"3","key":"1003_CR56","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood.2022017561","volume":"141","author":"K Lee","year":"2023","unstructured":"Lee K, Ahn HS, Estevez B, Poncz M. RUNX1-deficient human megakaryocytes demonstrate thrombopoietic and platelet half-life and functional defects. Blood. 2023;141(3):260\u201370.","journal-title":"Blood"},{"issue":"17","key":"1003_CR57","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood.2024023963","volume":"144","author":"N Kwon","year":"2024","unstructured":"Kwon N, Lu YC, Thompson EN, Mancuso RI, Wang L, Zhang PX, et al. CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors. Blood. 2024;144(17):1800\u201312.","journal-title":"Blood"},{"issue":"10","key":"1003_CR58","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1128\/MCB.23.10.3427-3441.2003","volume":"23","author":"M Eisbacher","year":"2003","unstructured":"Eisbacher M, Holmes ML, Newton A, Hogg PJ, Khachigian LM, Crossley M, et al. Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. Mol Cell Biol. 2003;23(10):3427\u201341.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"1003_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3892\/mmr.2024.13231","volume":"29","author":"C Wang","year":"2024","unstructured":"Wang C, Hu M, Yu K, Liu W, Hu A, Kuang Y, et al. An intricate regulatory circuit between FLI1 and GATA1\/GATA2\/LDB1\/ERG dictates erythroid vs. megakaryocytic differentiation. Mol Med Rep. 2024;29(6):107.","journal-title":"Mol Med Rep"},{"issue":"5","key":"1003_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0092-8674(95)90531-6","volume":"81","author":"RA Shivdasani","year":"1995","unstructured":"Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin\/MGDF in megakaryocyte development. Cell. 1995;81(5):695\u2013704.","journal-title":"Cell"},{"issue":"5","key":"1003_CR61","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.V92.5.1608","volume":"92","author":"P Lecine","year":"1998","unstructured":"Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA. Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood. 1998;92(5):1608\u201316.","journal-title":"Blood"},{"issue":"9","key":"1003_CR62","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.jtha.2023.04.007","volume":"21","author":"T Bigot","year":"2023","unstructured":"Bigot T, Gabinaud E, Hannouche L, Sbarra V, Andersen E, Bastelica D, et al. Single-cell analysis of megakaryopoiesis in peripheral CD34(+) cells: insights into ETV6-related thrombocytopenia. J Thromb Haemost. 2023;21(9):2528\u201344.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1003_CR63","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s42003-024-06090-z","volume":"7","author":"J Venhuizen","year":"2024","unstructured":"Venhuizen J, van Bergen M, Bergevoet SM, Gilissen D, Spruijt CG, Wingens L, et al. GFI1B and LSD1 repress myeloid traits during megakaryocyte differentiation. Commun Biol. 2024;7(1):374.","journal-title":"Commun Biol"},{"issue":"11","key":"1003_CR64","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/jth.12368","volume":"11","author":"WS Stevenson","year":"2013","unstructured":"Stevenson WS, Morel-Kopp MC, Chen Q, Liang HP, Bromhead CJ, Wright S, et al. GFI1B mutation causes a bleeding disorder with abnormal platelet function. J Thromb Haemost. 2013;11(11):2039\u201347.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1003_CR65","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa1308130","volume":"370","author":"D Monteferrario","year":"2014","unstructured":"Monteferrario D, Bolar NA, Marneth AE, Hebeda KM, Bergevoet SM, Veenstra H, et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med. 2014;370(3):245\u201353.","journal-title":"N Engl J Med"},{"issue":"10","key":"1003_CR66","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.3324\/haematol.2023.284951","volume":"109","author":"B Xu","year":"2024","unstructured":"Xu B, Ye X, Wen Z, Chen S, Wang J. Epigenetic regulation of megakaryopoiesis and platelet formation. Haematologica. 2024;109(10):3125\u201337.","journal-title":"Haematologica"},{"issue":"1","key":"1003_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40364-024-00614-9","volume":"12","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liu Z, Zhou P, Niu X, Sun Z, He H, et al. The involvement of kruppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate. Biomark Res. 2024;12(1):65.","journal-title":"Biomark Res"},{"issue":"12","key":"1003_CR68","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2008-09-180596","volume":"113","author":"EC Cheng","year":"2009","unstructured":"Cheng EC, Luo Q, Bruscia EM, Renda MJ, Troy JA, Massaro SA, et al. Role for MKL1 in megakaryocytic maturation. Blood. 2009;113(12):2826\u201334.","journal-title":"Blood"},{"issue":"16","key":"1003_CR69","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1182\/blood-2011-04-345876","volume":"118","author":"A Malara","year":"2011","unstructured":"Malara A, Gruppi C, Pallotta I, Spedden E, Tenni R, Raspanti M, et al. Extracellular matrix structure and nano-mechanics determine megakaryocyte function. Blood. 2011;118(16):4449\u201353.","journal-title":"Blood"},{"issue":"3","key":"1003_CR70","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ajh.25008","volume":"93","author":"O Leiva","year":"2018","unstructured":"Leiva O, Leon C, Kah Ng S, Mangin P, Gachet C, Ravid K. The role of extracellular matrix stiffness in megakaryocyte and platelet development and function. Am J Hematol. 2018;93(3):430\u201341.","journal-title":"Am J Hematol"},{"issue":"15","key":"1003_CR71","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/bloodadvances.2022008680","volume":"7","author":"I Guinard","year":"2023","unstructured":"Guinard I, Nguyen T, Brassard-Jollive N, Weber J, Ruch L, Reininger L, et al. Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgbeta3. Blood Adv. 2023;7(15):4003\u201318.","journal-title":"Blood Adv"},{"issue":"38","key":"1003_CR72","doi-asserted-by":"publisher","first-page":"e2407829121","DOI":"10.1073\/pnas.2407829121","volume":"121","author":"I Guinard","year":"2024","unstructured":"Guinard I, Brassard-Jollive N, Ruch L, Weber J, Eckly A, Boscher J, et al. Mechanical confinement prevents ectopic platelet release. Proc Natl Acad Sci U S A. 2024;121(38):e2407829121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1003_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/ATVBAHA.124.320392","volume":"45","author":"JE Italiano Jr","year":"2025","unstructured":"Italiano JE Jr., Payne C, Bekendam RH. Looking Under the Hood at the Cytoskeletal Engine of Platelet Production. Arterioscler Thromb Vasc Biol. 2025;45(2):186\u201397.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1003_CR74","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ajh.27184","volume":"99","author":"V Abbonante","year":"2024","unstructured":"Abbonante V, Karkempetzaki AI, Leon C, Krishnan A, Huang N, Di Buduo CA, et al. Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis. Am J Hematol. 2024;99(3):336\u201349.","journal-title":"Am J Hematol"},{"issue":"8","key":"1003_CR75","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s44161-023-00305-y","volume":"2","author":"MN Barrachina","year":"2023","unstructured":"Barrachina MN, Pernes G, Becker IC, Allaeys I, Hirsch TI, Groeneveld DJ, et al. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36. Nat Cardiovasc Res. 2023;2(8):746\u201363.","journal-title":"Nat Cardiovasc Res"},{"issue":"6","key":"1003_CR76","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.jtha.2025.02.043","volume":"23","author":"S Moog","year":"2025","unstructured":"Moog S, Mallo L, Eckly A, Janke C, Pujol A, Iruzubieta P, et al. Importance of tubulin detyrosination in platelet biogenesis. J Thromb Haemost. 2025;23(6):2025\u201334.","journal-title":"J Thromb Haemost"},{"issue":"17","key":"1003_CR77","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1182\/blood.2025028527","volume":"146","author":"H Wu","year":"2025","unstructured":"Wu H, Lu Y, Sun D, Miao Z, Chen S, Xia W, et al. circFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes. Blood. 2025;146(17):2119\u201332.","journal-title":"Blood"},{"issue":"16","key":"1003_CR78","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood.2025028460","volume":"146","author":"F Kollotzek","year":"2025","unstructured":"Kollotzek F, Mott K, Fischer M, Findik B, Gob V, Manke MC, et al. Casein kinase 1alpha essentially regulates thrombopoiesis by driving megakaryocyte maturation and cytoskeleton organization. Blood. 2025;146(16):1964\u201378.","journal-title":"Blood"},{"issue":"12","key":"1003_CR79","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.stemcr.2025.102720","volume":"20","author":"E Sung","year":"2025","unstructured":"Sung E, Murakami S, Morita M, Ida T, Akaike T, Motohashi H. Mitochondria regulate the cell fate decisions of megakaryocyte-erythroid progenitors. Stem Cell Rep. 2025;20(12):102720.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"1003_CR80","doi-asserted-by":"publisher","first-page":"117339","DOI":"10.1016\/j.celrep.2026.117339","volume":"45","author":"X Li","year":"2026","unstructured":"Li X, Qi J, Chu T, Hou Q, Han H, Zhang Z, et al. MELK inhibition promotes megakaryopoiesis and platelet recovery in models of immune thrombocytopenia through ERK\/cofilin signaling. Cell Rep. 2026;45(5):117339.","journal-title":"Cell Rep"},{"issue":"11","key":"1003_CR81","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/blood.2025031490","volume":"148","author":"MF Chiu","year":"2026","unstructured":"Chiu MF, Yeh KH, Chen PJ, Chou WC, Lin CW, Chang KP, et al. FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features. Blood. 2026;148(11):1440\u201353.","journal-title":"Blood"},{"key":"1003_CR82","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.mito.2026.102192","volume":"91","author":"SW Chen","year":"2026","unstructured":"Chen SW, Chen HW, Chu CH, Hsu PS, Yu YS, Lin SP, et al. Mitochondrial translocation of DNMT3L suppresses oxidative phosphorylation and restrains megakaryopoiesis. Mitochondrion. 2026;91:102192.","journal-title":"Mitochondrion"},{"issue":"5","key":"1003_CR83","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/bloodadvances.2024014805","volume":"9","author":"X Lin","year":"2025","unstructured":"Lin X, Gao H, Xin M, Huang J, Li X, Zhou Y, et al. alpha-Actinin-1 deficiency in megakaryocytes causes low platelet count, platelet dysfunction, and mitochondrial impairment. Blood Adv. 2025;9(5):1185\u2013201.","journal-title":"Blood Adv"},{"issue":"1","key":"1003_CR84","doi-asserted-by":"publisher","first-page":"13159","DOI":"10.1038\/s41598-025-95946-3","volume":"15","author":"P Liu","year":"2025","unstructured":"Liu P, Yuan X, Liu Y, Guo M, Xu L, Dong Q, et al. RHOB regulates megakaryocytic and erythroid differentiation by altering the cell cycle and cytoskeleton. Sci Rep. 2025;15(1):13159.","journal-title":"Sci Rep"},{"issue":"1","key":"1003_CR85","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1182\/bloodadvances.2025017375","volume":"10","author":"V Camacho","year":"2026","unstructured":"Camacho V, Bekendam RH, Stone AP, Barrachina MN, Branfield S, Carminita E, et al. Induction of moderate DNA damage enhances megakaryopoiesis and platelet production. Blood Adv. 2026;10(1):155\u201367.","journal-title":"Blood Adv"},{"issue":"8","key":"1003_CR86","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1007\/s11427-025-3256-7","volume":"69","author":"Y Yuan","year":"2026","unstructured":"Yuan Y, Ai J, Chen H, Zhang P, Leng F, Guo K, et al. The KXD1-TSPAN14 axis controls megakaryopoiesis and platelet production via Notch signaling. Sci China Life Sci. 2026;69(8):2754\u201371.","journal-title":"Sci China Life Sci"},{"issue":"11","key":"1003_CR87","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood.2025031904","volume":"148","author":"K Ramaekers","year":"2026","unstructured":"Ramaekers K, Tran M, Lunghi M, Hermans A, Thys C, De Wispelaere K, et al. Reduced platelet formation associated with serine metabolic dysregulation in integrin alphaIIbbeta3-deficient megakaryocytes. Blood. 2026;148(11):1466\u201380.","journal-title":"Blood"},{"issue":"7","key":"1003_CR88","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3324\/haematol.2024.287236","volume":"110","author":"C Du","year":"2025","unstructured":"Du C, Chen J, Wang J. New insights into the generation and function of megakaryocytes in health and disease. Haematologica. 2025;110(7):1500\u201312.","journal-title":"Haematologica"},{"issue":"11","key":"1003_CR89","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm.3706","volume":"20","author":"M Zhao","year":"2014","unstructured":"Zhao M, Perry JM, Marshall H, Venkatraman A, Qian P, He XC, et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med. 2014;20(11):1321\u20136.","journal-title":"Nat Med"},{"issue":"11","key":"1003_CR90","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nm.3707","volume":"20","author":"I Bruns","year":"2014","unstructured":"Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315\u201320.","journal-title":"Nat Med"},{"issue":"2","key":"1003_CR91","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bbrc.2014.10.095","volume":"454","author":"A Nakamura-Ishizu","year":"2014","unstructured":"Nakamura-Ishizu A, Takubo K, Fujioka M, Suda T. Megakaryocytes are essential for HSC quiescence through the production of thrombopoietin. Biochem Biophys Res Commun. 2014;454(2):353\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"1003_CR92","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1073\/pnas.1404354111","volume":"111","author":"AP Ng","year":"2014","unstructured":"Ng AP, Kauppi M, Metcalf D, Hyland CD, Josefsson EC, Lebois M, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A. 2014;111(16):5884\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6384","key":"1003_CR93","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/science.aap8861","volume":"360","author":"M Decker","year":"2018","unstructured":"Decker M, Leslie J, Liu Q, Ding L. Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance. Science. 2018;360(6384):106\u201310.","journal-title":"Science"},{"issue":"7571","key":"1003_CR94","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature15250","volume":"526","author":"M Acar","year":"2015","unstructured":"Acar M, Kocherlakota KS, Murphy MM, Peyer JG, Oguro H, Inra CN, et al. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature. 2015;526(7571):126\u201330.","journal-title":"Nature"},{"issue":"5","key":"1003_CR95","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.devcel.2018.01.016","volume":"44","author":"S Pinho","year":"2018","unstructured":"Pinho S, Marchand T, Yang E, Wei Q, Nerlov C, Frenette PS. Lineage-Biased Hematopoietic Stem Cells Are Regulated by Distinct Niches. Dev Cell. 2018;44(5):634\u201341. e4.","journal-title":"Dev Cell"},{"issue":"7473","key":"1003_CR96","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature12612","volume":"502","author":"Y Kunisaki","year":"2013","unstructured":"Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502(7473):637\u201343.","journal-title":"Nature"},{"issue":"26","key":"1003_CR97","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1182\/blood-2012-10-463414","volume":"121","author":"TS Olson","year":"2013","unstructured":"Olson TS, Caselli A, Otsuru S, Hofmann TJ, Williams R, Paolucci P, et al. Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. Blood. 2013;121(26):5238\u201349.","journal-title":"Blood"},{"issue":"1","key":"1003_CR98","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-025-01687-1","volume":"18","author":"O Herranz","year":"2025","unstructured":"Herranz O, Berrocal P, Sicilia-Navarro C, Fernandez-Infante C, Hernandez-Cano L, Porras A, et al. C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function. J Hematol Oncol. 2025;18(1):38.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1003_CR99","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1038\/s41467-023-41691-y","volume":"14","author":"TC Luis","year":"2023","unstructured":"Luis TC, Barkas N, Carrelha J, Giustacchini A, Mazzi S, Norfo R, et al. Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner. Nat Commun. 2023;14(1):6062.","journal-title":"Nat Commun"},{"key":"1003_CR100","doi-asserted-by":"publisher","first-page":"840044","DOI":"10.3389\/fonc.2022.840044","volume":"12","author":"E Khatib-Massalha","year":"2022","unstructured":"Khatib-Massalha E, Mendez-Ferrer S. Megakaryocyte Diversity in Ontogeny, Functions and Cell-Cell Interactions. Front Oncol. 2022;12:840044.","journal-title":"Front Oncol"},{"key":"1003_CR101","doi-asserted-by":"publisher","first-page":"912060","DOI":"10.3389\/fonc.2022.912060","volume":"12","author":"H Zhan","year":"2022","unstructured":"Zhan H, Kaushansky K. Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche. Front Oncol. 2022;12:912060.","journal-title":"Front Oncol"},{"issue":"7","key":"1003_CR102","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/trf.17927","volume":"64","author":"S Chen","year":"2024","unstructured":"Chen S, Looney MR. Understanding megakaryocyte phenotypes and the impact on platelet biogenesis. Transfusion. 2024;64(7):1372\u201380.","journal-title":"Transfusion"},{"issue":"1","key":"1003_CR103","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40364-025-00830-x","volume":"13","author":"P Lee","year":"2025","unstructured":"Lee P, Balbi C, Allemann MS, Ghosh A, Wang T, Bacigaluppi M, et al. Age- and sex-specific transcriptomic changes drive the prothrombotic potential of megakaryocytes. Biomark Res. 2025;13(1):128.","journal-title":"Biomark Res"},{"issue":"23","key":"1003_CR104","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood.2024027432","volume":"146","author":"S Zhang","year":"2025","unstructured":"Zhang S, Ayemoba CE, Di Staulo AM, Joves K, Patel CM, Leung EHW, et al. Platelet factor 4 regulates hematopoietic stem cell aging. Blood. 2025;146(23):2765\u201378.","journal-title":"Blood"},{"issue":"12","key":"1003_CR105","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/leu.2016.114","volume":"30","author":"H Zhan","year":"2016","unstructured":"Zhan H, Ma Y, Lin CH, Kaushansky K. JAK2(V617F)-mutant megakaryocytes contribute to hematopoietic stem\/progenitor cell expansion in a model of murine myeloproliferation. Leukemia. 2016;30(12):2332\u201341.","journal-title":"Leukemia"},{"issue":"19","key":"1003_CR106","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","volume":"25","author":"B Woods","year":"2019","unstructured":"Woods B, Chen W, Chiu S, Marinaccio C, Fu C, Gu L, et al. Activation of JAK\/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo. Clin Cancer Res. 2019;25(19):5901\u201312.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1003_CR107","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/stmcls\/sxac005","volume":"40","author":"S Lee","year":"2022","unstructured":"Lee S, Wong H, Castiglione M, Murphy M, Kaushansky K, Zhan H. JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm. Stem Cells. 2022;40(4):359\u201370.","journal-title":"Stem Cells"},{"issue":"7","key":"1003_CR108","first-page":"2403","volume":"111","author":"X Yang","year":"2026","unstructured":"Yang X, Lee S, Masarik K, Ahmed T, Zheng L, Zhan H. Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms. Haematologica. 2026;111(7):2403\u201316.","journal-title":"Haematologica"},{"issue":"11","key":"1003_CR109","doi-asserted-by":"publisher","first-page":"e199690","DOI":"10.1172\/JCI199690","volume":"136","author":"S Zhang","year":"2026","unstructured":"Zhang S, Liu J, Li Y, Wang Y, Wang L, Xu M, et al. Physiological MplW514L expression in hematopoietic stem cell causes an essential thrombocythemia and progressive myelofibrosis. J Clin Invest. 2026;136(11):e199690.","journal-title":"J Clin Invest"},{"issue":"4","key":"1003_CR110","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/stem.1626","volume":"32","author":"A Malara","year":"2014","unstructured":"Malara A, Currao M, Gruppi C, Celesti G, Viarengo G, Buracchi C, et al. Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin. Stem Cells. 2014;32(4):926\u201337.","journal-title":"Stem Cells"},{"issue":"7","key":"1003_CR111","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3324\/haematol.2016.161562","volume":"102","author":"V Abbonante","year":"2017","unstructured":"Abbonante V, Di Buduo CA, Gruppi C, De Maria C, Spedden E, De Acutis A, et al. A new path to platelet production through matrix sensing. Haematologica. 2017;102(7):1150\u201360.","journal-title":"Haematologica"},{"issue":"4","key":"1003_CR112","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/stem.2285","volume":"34","author":"V Abbonante","year":"2016","unstructured":"Abbonante V, Di Buduo CA, Gruppi C, Malara A, Gianelli U, Celesti G, et al. Thrombopoietin\/TGF-beta1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. Stem Cells. 2016;34(4):1123\u201333.","journal-title":"Stem Cells"},{"key":"1003_CR113","doi-asserted-by":"publisher","first-page":"RP104963","DOI":"10.7554\/eLife.104963.4","volume":"14","author":"C Masson","year":"2025","unstructured":"Masson C, Scandola C, Rinckel JY, Proamer F, Janus-Bell E, Batool F, et al. Megakaryocytes assemble a three-dimensional cage of extracellular matrix that controls their maturation and anchoring to the vascular niche. Elife. 2025;14:RP104963.","journal-title":"Elife"},{"issue":"31","key":"1003_CR114","doi-asserted-by":"publisher","first-page":"27630","DOI":"10.1074\/jbc.M111.243113","volume":"286","author":"A Eliades","year":"2011","unstructured":"Eliades A, Papadantonakis N, Bhupatiraju A, Burridge KA, Johnston-Cox HA, Migliaccio AR, et al. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem. 2011;286(31):27630\u20138.","journal-title":"J Biol Chem"},{"issue":"6","key":"1003_CR115","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","volume":"130","author":"V Abbonante","year":"2017","unstructured":"Abbonante V, Chitalia V, Rosti V, Leiva O, Matsuura S, Balduini A, et al. Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis. Blood. 2017;130(6):829\u201331.","journal-title":"Blood"},{"issue":"6","key":"1003_CR116","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ncb3530","volume":"19","author":"M Decker","year":"2017","unstructured":"Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat Cell Biol. 2017;19(6):677\u201388.","journal-title":"Nat Cell Biol"},{"issue":"9","key":"1003_CR117","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20160283","volume":"213","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213(9):1723\u201340.","journal-title":"J Exp Med"},{"issue":"2","key":"1003_CR118","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","volume":"35","author":"Y Ozono","year":"2021","unstructured":"Ozono Y, Shide K, Kameda T, Kamiunten A, Tahira Y, Sekine M, et al. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia. 2021;35(2):454\u201367.","journal-title":"Leukemia"},{"issue":"12","key":"1003_CR119","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.3390\/cells10123302","volume":"10","author":"AR Migliaccio","year":"2021","unstructured":"Migliaccio AR. A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis. Cells. 2021;10(12):3302.","journal-title":"Cells"},{"key":"1003_CR120","doi-asserted-by":"publisher","first-page":"853484","DOI":"10.3389\/fonc.2022.853484","volume":"12","author":"P Verachi","year":"2022","unstructured":"Verachi P, Gobbo F, Martelli F, Martinelli A, Sarli G, Dunbar A, et al. The CXCR1\/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 (low) Mice. Front Oncol. 2022;12:853484.","journal-title":"Front Oncol"},{"issue":"25","key":"1003_CR121","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood.2019004230","volume":"135","author":"S Matsuura","year":"2020","unstructured":"Matsuura S, Thompson CR, Ng SK, Ward CM, Karagianni A, Mazzeo C, et al. Adhesion to fibronectin via alpha5beta1 integrin supports expansion of the megakaryocyte lineage in primary myelofibrosis. Blood. 2020;135(25):2286\u201391.","journal-title":"Blood"},{"issue":"1","key":"1003_CR122","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nm973","volume":"10","author":"ST Avecilla","year":"2004","unstructured":"Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10(1):64\u201371.","journal-title":"Nat Med"},{"issue":"5","key":"1003_CR123","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.bone.2006.05.019","volume":"39","author":"MA Kacena","year":"2006","unstructured":"Kacena MA, Gundberg CM, Horowitz MC. A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone. 2006;39(5):978\u201384.","journal-title":"Bone"},{"issue":"1","key":"1003_CR124","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s40364-024-00700-y","volume":"12","author":"M Yan","year":"2024","unstructured":"Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q. Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy. Biomark Res. 2024;12(1):164.","journal-title":"Biomark Res"},{"issue":"15","key":"1003_CR125","doi-asserted-by":"publisher","first-page":"e2100921","DOI":"10.1002\/advs.202100921","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu C, Wu D, Xia M, Li M, Sun Z, Shen B, et al. Characterization of Cellular Heterogeneity and an Immune Subpopulation of Human Megakaryocytes. Adv Sci (Weinh). 2021;8(15):e2100921.","journal-title":"Adv Sci (Weinh)"},{"issue":"14","key":"1003_CR126","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2021010697","volume":"138","author":"S Sun","year":"2021","unstructured":"Sun S, Jin C, Si J, Lei Y, Chen K, Cui Y, et al. Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis. Blood. 2021;138(14):1211\u201324.","journal-title":"Blood"},{"issue":"2","key":"1003_CR127","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCRESAHA.121.319821","volume":"130","author":"M Koupenova","year":"2022","unstructured":"Koupenova M, Livada AC, Morrell CN. Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity. Circ Res. 2022;130(2):288\u2013308.","journal-title":"Circ Res"},{"key":"1003_CR128","doi-asserted-by":"publisher","first-page":"e78662","DOI":"10.7554\/eLife.78662","volume":"11","author":"J Wang","year":"2022","unstructured":"Wang J, Xie J, Wang D, Han X, Chen M, Shi G, et al. CXCR4(high) megakaryocytes regulate host-defense immunity against bacterial pathogens. Elife. 2022;11:e78662.","journal-title":"Elife"},{"issue":"7648","key":"1003_CR129","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature21706","volume":"544","author":"E Lefrancais","year":"2017","unstructured":"Lefrancais E, Ortiz-Munoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105\u20139.","journal-title":"Nature"},{"issue":"1","key":"1003_CR130","doi-asserted-by":"publisher","first-page":"e137377","DOI":"10.1172\/JCI137377","volume":"131","author":"DN Pariser","year":"2021","unstructured":"Pariser DN, Hilt ZT, Ture SK, Blick-Nitko SK, Looney MR, Cleary SJ, et al. Lung megakaryocytes are immune modulatory cells. J Clin Invest. 2021;131(1):e137377.","journal-title":"J Clin Invest"},{"issue":"24","key":"1003_CR131","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1182\/bloodadvances.2020002843","volume":"4","author":"AK Yeung","year":"2020","unstructured":"Yeung AK, Villacorta-Martin C, Hon S, Rock JR, Murphy GJ. Lung megakaryocytes display distinct transcriptional and phenotypic properties. Blood Adv. 2020;4(24):6204\u201317.","journal-title":"Blood Adv"},{"issue":"1","key":"1003_CR132","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1038\/s41467-024-51686-y","volume":"15","author":"J Qiu","year":"2024","unstructured":"Qiu J, Ma J, Dong Z, Ren Q, Shan Q, Liu J, et al. Lung megakaryocytes engulf inhaled airborne particles to promote intrapulmonary inflammation and extrapulmonary distribution. Nat Commun. 2024;15(1):7396.","journal-title":"Nat Commun"},{"key":"1003_CR133","doi-asserted-by":"publisher","unstructured":"Guo X, Dai Q, Liao X, Ma Y, Liu H, Xiong J, et al. Pulmonary megakaryocytes orchestrate host defense via PcrV-induced NF-kappaB signaling in Pseudomonas aeruginosa infection. Cell Commun Signal. 2026. https:\/\/doi.org\/10.1186\/s12964-026-03072-y.","DOI":"10.1186\/s12964-026-03072-y"},{"issue":"2","key":"1003_CR134","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3324\/haematol.2017.178988","volume":"103","author":"WJ Wong","year":"2018","unstructured":"Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018;103(2):e63\u20138.","journal-title":"Haematologica"},{"issue":"1","key":"1003_CR135","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","volume":"482","author":"U Gianelli","year":"2023","unstructured":"Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, et al. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023;482(1):53\u201368.","journal-title":"Virchows Arch"},{"issue":"5","key":"1003_CR136","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801\u201321.","journal-title":"Am J Hematol"},{"issue":"12","key":"1003_CR137","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.3324\/haematol.2020.264143","volume":"106","author":"M Schino","year":"2021","unstructured":"Schino M, Fiorentino V, Rossi E, Betti S, Di Cecca M, Ranucci V, et al. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2021;106(12):3162\u20139.","journal-title":"Haematologica"},{"issue":"11","key":"1003_CR138","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"G Wernig","year":"2006","unstructured":"Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274\u201381.","journal-title":"Blood"},{"issue":"1","key":"1003_CR139","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.leu.2405043","volume":"22","author":"K Shide","year":"2008","unstructured":"Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008;22(1):87\u201395.","journal-title":"Leukemia"},{"issue":"9","key":"1003_CR140","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","volume":"116","author":"J Li","year":"2010","unstructured":"Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528\u201338.","journal-title":"Blood"},{"issue":"10","key":"1003_CR141","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317\u201324.","journal-title":"Blood"},{"issue":"6","key":"1003_CR142","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","volume":"131","author":"J Li","year":"2018","unstructured":"Li J, Prins D, Park HJ, Grinfeld J, Gonzalez-Arias C, Loughran S, et al. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood. 2018;131(6):649\u201361.","journal-title":"Blood"},{"issue":"7","key":"1003_CR143","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631\u201342.","journal-title":"Leukemia"},{"issue":"S1","key":"1003_CR144","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.5045\/br.2023.2023038","volume":"58","author":"J Hong","year":"2023","unstructured":"Hong J. Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Res. 2023;58(S1):S37\u201345.","journal-title":"Blood Res"},{"issue":"16","key":"1003_CR145","doi-asserted-by":"publisher","first-page":"13008","DOI":"10.3390\/ijms241613008","volume":"24","author":"S Morishita","year":"2023","unstructured":"Morishita S, Komatsu N. Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms. Int J Mol Sci. 2023;24(16):13008.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1003_CR146","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3324\/haematol.2021.280320","volume":"108","author":"Z Shi","year":"2023","unstructured":"Shi Z, Liu J, Zhao Y, Yang L, Cai Y, Zhang P, et al. ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms. Haematologica. 2023;108(5):1359\u201373.","journal-title":"Haematologica"},{"issue":"9","key":"1003_CR147","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1038\/s41375-025-02684-6","volume":"39","author":"W Zhang","year":"2025","unstructured":"Zhang W, Li B, Liu J, Yan Y, Yang L, Qin T, et al. Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1(S34F) mutant myelodysplastic neoplasms. Leukemia. 2025;39(9):2246\u201355.","journal-title":"Leukemia"},{"issue":"5","key":"1003_CR148","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41375-025-02576-9","volume":"39","author":"H Takamori","year":"2025","unstructured":"Takamori H, Huang YJ, Fukushima H, Yokoyama K, Huang TY, Kuo MC, et al. Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation. Leukemia. 2025;39(5):1218\u201327.","journal-title":"Leukemia"},{"issue":"8","key":"1003_CR149","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.ccell.2026.06.008","volume":"44","author":"J Wen","year":"2026","unstructured":"Wen J, Cotton A, Mehmood R, Mohan M, Hall T, Broadhurst AL, et al. Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms. Cancer Cell. 2026;44(8):1639\u201352. e6.","journal-title":"Cancer Cell"},{"key":"1003_CR150","doi-asserted-by":"publisher","first-page":"584541","DOI":"10.3389\/fonc.2020.584541","volume":"10","author":"M Zingariello","year":"2020","unstructured":"Zingariello M, Rosti V, Vannucchi AM, Guglielmelli P, Mazzarini M, Barosi G, et al. Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. Front Oncol. 2020;10:584541.","journal-title":"Front Oncol"},{"issue":"11","key":"1003_CR151","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1172\/JCI64397","volume":"122","author":"X Wang","year":"2012","unstructured":"Wang X, Prakash S, Lu M, Tripodi J, Ye F, Najfeld V, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012;122(11):3888\u201399.","journal-title":"J Clin Invest"},{"issue":"2","key":"1003_CR152","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.exphem.2014.10.013","volume":"43","author":"X Wang","year":"2015","unstructured":"Wang X, Cho SY, Hu CS, Chen D, Roboz J, Hoffman R. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol. 2015;43(2):100\u20139. e1.","journal-title":"Exp Hematol"},{"issue":"9","key":"1003_CR153","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.stem.2026.08.002","volume":"33","author":"R Austin","year":"2026","unstructured":"Austin R, Kowalski MH, Wang X, Lin Z, Nadorp B, Ward N, et al. Splenic extramedullary hematopoiesis in myelofibrosis is shaped by transcriptomic and epigenetic dysregulation. Cell Stem Cell. 2026;33(9):1495\u2013e51313.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"1003_CR154","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.25047","volume":"93","author":"MA Avanzini","year":"2018","unstructured":"Avanzini MA, Abbonante V, Catarsi P, Dambruoso I, Mantelli M, Poletto V, et al. The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. Am J Hematol. 2018;93(5):615\u201322.","journal-title":"Am J Hematol"},{"issue":"1","key":"1003_CR155","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/stem.2229","volume":"34","author":"GJ Spangrude","year":"2016","unstructured":"Spangrude GJ, Lewandowski D, Martelli F, Marra M, Zingariello M, Sancillo L, et al. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells. 2016;34(1):67\u201382.","journal-title":"Stem Cells"},{"key":"1003_CR156","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.exphem.2022.09.004","volume":"117","author":"P Verachi","year":"2023","unstructured":"Verachi P, Gobbo F, Martelli F, Falchi M, di Virgilio A, Sarli G, et al. Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1(low) mouse model. Exp Hematol. 2023;117:43\u201361.","journal-title":"Exp Hematol"},{"issue":"9","key":"1003_CR157","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.stem.2026.07.012","volume":"33","author":"B Dugue","year":"2026","unstructured":"Dugue B, Wanner P, Ruiz Tejada Segura ML, Saad M, Greven L, Gotz K, et al. Spatial profiling of the spleen in mouse and human myelofibrosis reveals complement-driven immune-stromal interactions as a therapeutic target. Cell Stem Cell. 2026;33(9):1477\u2013e9414.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"1003_CR158","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.ajpath.2017.04.006","volume":"187","author":"BG Erba","year":"2017","unstructured":"Erba BG, Gruppi C, Corada M, Pisati F, Rosti V, Bartalucci N, et al. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. Am J Pathol. 2017;187(8):1879\u201392.","journal-title":"Am J Pathol"},{"issue":"10","key":"1003_CR159","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","volume":"100","author":"H Chagraoui","year":"2002","unstructured":"Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100(10):3495\u2013503.","journal-title":"Blood"},{"issue":"2","key":"1003_CR160","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stemcr.2023.12.011","volume":"19","author":"N Flosdorf","year":"2024","unstructured":"Flosdorf N, Bohnke J, de Toledo MAS, Lutterbach N, Lerma VG, Grasshoff M, et al. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche. Stem Cell Rep. 2024;19(2):224\u201338.","journal-title":"Stem Cell Rep"},{"issue":"9","key":"1003_CR161","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41375-024-02354-z","volume":"38","author":"D Capitanio","year":"2024","unstructured":"Capitanio D, Calledda FR, Abbonante V, Cattaneo D, Moriggi M, Bartalucci N, et al. Proteomic screening identifies PF4\/Cxcl4 as a critical driver of myelofibrosis. Leukemia. 2024;38(9):1971\u201384.","journal-title":"Leukemia"},{"issue":"768","key":"1003_CR162","doi-asserted-by":"publisher","first-page":"eadj7552","DOI":"10.1126\/scitranslmed.adj7552","volume":"16","author":"R Li","year":"2024","unstructured":"Li R, Colombo M, Wang G, Rodriguez-Romera A, Benlabiod C, Jooss NJ, et al. A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis. Sci Transl Med. 2024;16(768):eadj7552.","journal-title":"Sci Transl Med"},{"issue":"23","key":"1003_CR163","doi-asserted-by":"publisher","first-page":"e173665","DOI":"10.1172\/jci.insight.173665","volume":"9","author":"S Ganesan","year":"2024","unstructured":"Ganesan S, Awan-Toor S, Guidez F, Maslah N, Rahimy R, Aoun C, et al. Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-beta\/WNT\/HOXB7 axis in patients with myelofibrosis. JCI Insight. 2024;9(23):e173665.","journal-title":"JCI Insight"},{"issue":"11","key":"1003_CR164","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1182\/blood.2025031454","volume":"147","author":"M Lu","year":"2026","unstructured":"Lu M, Mia MB, Xia L, Mosoyan G, Hayat M, Schaniel C, et al. Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells. Blood. 2026;147(11):1215\u201328.","journal-title":"Blood"},{"issue":"1\u20132","key":"1003_CR165","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/10428199509054751","volume":"20","author":"MC Martyre","year":"1995","unstructured":"Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma. 1995;20(1\u20132):39\u201344.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1003_CR166","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<133::AID-AJH6>3.0.CO;2-Z","volume":"59","author":"P Rameshwar","year":"1998","unstructured":"Rameshwar P, Chang VT, Thacker UF, Gascon P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis\u2013pathophysiological implications. Am J Hematol. 1998;59(2):133\u201342.","journal-title":"Am J Hematol"},{"issue":"2","key":"1003_CR167","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0369-8114(00)00021-3","volume":"49","author":"MC Le Bousse-Kerdiles","year":"2001","unstructured":"Le Bousse-Kerdiles MC, Martyre MC, French IIM. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris). 2001;49(2):153\u20137.","journal-title":"Pathol Biol (Paris)"},{"issue":"Pt 2","key":"1003_CR168","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1242\/jcs.00229","volume":"116","author":"JP Annes","year":"2003","unstructured":"Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116(Pt 2):217\u201324.","journal-title":"J Cell Sci"},{"issue":"6","key":"1003_CR169","doi-asserted-by":"publisher","first-page":"a021907","DOI":"10.1101\/cshperspect.a021907","volume":"8","author":"IB Robertson","year":"2016","unstructured":"Robertson IB, Rifkin DB. Regulation of the Bioavailability of TGF-beta and TGF-beta-Related Proteins. Cold Spring Harb Perspect Biol. 2016;8(6):a021907.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"1003_CR170","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood.2022017097","volume":"141","author":"S Lecomte","year":"2023","unstructured":"Lecomte S, Devreux J, de Streel G, van Baren N, Havelange V, Schroder D, et al. Therapeutic activity of GARP:TGF-beta1 blockade in murine primary myelofibrosis. Blood. 2023;141(5):490\u2013502.","journal-title":"Blood"},{"issue":"11","key":"1003_CR171","doi-asserted-by":"publisher","first-page":"e154092","DOI":"10.1172\/JCI154092","volume":"132","author":"JC Yao","year":"2022","unstructured":"Yao JC, Oetjen KA, Wang T, Xu H, Abou-Ezzi G, Krambs JR, et al. TGF-beta signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. J Clin Invest. 2022;132(11):e154092.","journal-title":"J Clin Invest"},{"issue":"4","key":"1003_CR172","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0268-960X(89)90034-9","volume":"3","author":"K Miyazono","year":"1989","unstructured":"Miyazono K, Takaku F. Platelet-derived growth factors. Blood Rev. 1989;3(4):269\u201376.","journal-title":"Blood Rev"},{"issue":"3\u20134","key":"1003_CR173","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/10428199509059613","volume":"18","author":"A Kimura","year":"1995","unstructured":"Kimura A, Katoh O, Hyodo H, Kuramoto A, Satow Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leuk Lymphoma. 1995;18(3\u20134):237\u201342.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1003_CR174","first-page":"34","volume":"53","author":"G Gadomska","year":"2017","unstructured":"Gadomska G, Stankowska K, Boinska J, Slusarz R, Tylicka M, Michalska M, et al. VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. Med (Kaunas). 2017;53(1):34\u20139.","journal-title":"Med (Kaunas)"},{"issue":"2","key":"1003_CR175","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1073\/pnas.94.2.663","volume":"94","author":"R Mohle","year":"1997","unstructured":"Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94(2):663\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1003_CR176","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3324\/haematol.2019.226332","volume":"105","author":"F Kramer","year":"2020","unstructured":"Kramer F, Dernedde J, Mezheyeuski A, Tauber R, Micke P, Kappert K. Platelet-derived growth factor receptor beta activation and regulation in murine myelofibrosis. Haematologica. 2020;105(8):2083\u201394.","journal-title":"Haematologica"},{"issue":"5","key":"1003_CR177","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/MOH.0000000000000669","volume":"28","author":"HFE Gleitz","year":"2021","unstructured":"Gleitz HFE, Benabid A, Schneider RK. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms. Curr Opin Hematol. 2021;28(5):364\u201371.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"1003_CR178","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/ph17010109","volume":"17","author":"M Huang","year":"2024","unstructured":"Huang M, Wang L, Zhang Q, Zhou L, Liao R, Wu A, et al. Interleukins in Platelet Biology: Unraveling the Complex Regulatory Network. Pharmaceuticals (Basel). 2024;17(1):109.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"1003_CR179","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia. 2019;33(8):1978\u201395.","journal-title":"Leukemia"},{"issue":"20","key":"1003_CR180","first-page":"2508","volume":"141","author":"AJ Dunbar","year":"2023","unstructured":"Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, et al. CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023;141(20):2508\u201319.","journal-title":"Blood"},{"issue":"7","key":"1003_CR181","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3324\/haematol.2023.284921","volume":"109","author":"G Vermeersch","year":"2024","unstructured":"Vermeersch G, Proost P, Struyf S, Gouwy M, Devos T. CXCL8 and its cognate receptors CXCR1\/CXCR2 in primary myelofibrosis. Haematologica. 2024;109(7):2060\u201372.","journal-title":"Haematologica"},{"issue":"26","key":"1003_CR182","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood.2022017326","volume":"140","author":"J Melo-Cardenas","year":"2022","unstructured":"Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, et al. IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 2022;140(26):2805\u201317.","journal-title":"Blood"},{"issue":"1","key":"1003_CR183","doi-asserted-by":"publisher","first-page":"43716","DOI":"10.1038\/s41598-025-27594-6","volume":"15","author":"DB Yanuk","year":"2025","unstructured":"Yanuk DB, Cellucci AS, Marta RF, Discianni Lupi AD, De Luca G, Glembotsky AC, et al. Inflammatory mediators differentially regulate megakaryopoiesis and thrombopoiesis in myelofibrosis and essential thrombocythemia. Sci Rep. 2025;15(1):43716.","journal-title":"Sci Rep"},{"issue":"1","key":"1003_CR184","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","volume":"13","author":"S Rai","year":"2022","unstructured":"Rai S, Grockowiak E, Hansen N, Luque Paz D, Stoll CB, Hao-Shen H, et al. Inhibition of interleukin-1beta reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022;13(1):5346.","journal-title":"Nat Commun"},{"issue":"1","key":"1003_CR185","doi-asserted-by":"publisher","first-page":"10591","DOI":"10.1038\/s41467-025-65673-4","volume":"16","author":"RM Koerber","year":"2025","unstructured":"Koerber RM, Krollmann C, Cieslak K, Tregel E, Saenz ML, Brummendorf TH, et al. NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms. Nat Commun. 2025;16(1):10591.","journal-title":"Nat Commun"},{"key":"1003_CR186","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.freeradbiomed.2026.07.030","volume":"255","author":"L Longhitano","year":"2026","unstructured":"Longhitano L, La Spina E, Giallongo S, Giallongo C, Ferrigno J, Orlando L, et al. Heme oxygenase-1\/CO signaling suppresses NLRP3 inflammasome-mediated stromal fibrosis in primary myelofibrosis. Free Radic Biol Med. 2026;255:275\u201388.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1003_CR187","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/bjh.13471","volume":"172","author":"V Abbonante","year":"2016","unstructured":"Abbonante V, Gruppi C, Catarsi P, Avanzini MA, Tira ME, Barosi G, et al. Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells. Br J Haematol. 2016;172(1):140\u20134.","journal-title":"Br J Haematol"},{"issue":"19","key":"1003_CR188","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2018-02-834820","volume":"131","author":"R Kramann","year":"2018","unstructured":"Kramann R, Schneider RK. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood. 2018;131(19):2111\u20139.","journal-title":"Blood"},{"issue":"6","key":"1003_CR189","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.stem.2023.05.002","volume":"30","author":"SM Sarkaria","year":"2023","unstructured":"Sarkaria SM, Zhou J, Bao S, Zhao W, Fang Y, Que J, et al. Systematic dissection of coordinated stromal remodeling identifies Sox10(+) glial cells as a therapeutic target in myelofibrosis. Cell Stem Cell. 2023;30(6):832\u201350. e6.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"1003_CR190","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","volume":"28","author":"NB Leimkuhler","year":"2021","unstructured":"Leimkuhler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021;28(4):637\u201352. e8.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"1003_CR191","doi-asserted-by":"publisher","first-page":"e70179","DOI":"10.1002\/hem3.70179","volume":"9","author":"HFE Gleitz","year":"2025","unstructured":"Gleitz HFE, Fuchs SNR, Snoeren IAM, Boys C, Nagai J, Tejeda-Mora H, et al. Inhibiting the alarmin-driven hematopoiesis-stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis. Hemasphere. 2025;9(8):e70179.","journal-title":"Hemasphere"},{"issue":"12","key":"1003_CR192","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/leu.2017.112","volume":"31","author":"T Maekawa","year":"2017","unstructured":"Maekawa T, Osawa Y, Izumi T, Nagao S, Takano K, Okada Y, et al. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis. Leukemia. 2017;31(12):2709\u201316.","journal-title":"Leukemia"},{"key":"1003_CR193","doi-asserted-by":"publisher","unstructured":"Uchida T, Shide K, Kameda T, Ozono Y, Kubuki Y, Tahira Y, et al. Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032693.","DOI":"10.1182\/blood.2025032693"},{"issue":"1","key":"1003_CR194","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4049\/jimmunol.171.1.380","volume":"171","author":"M Schmidt","year":"2003","unstructured":"Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol. 2003;171(1):380\u20139.","journal-title":"J Immunol"},{"issue":"10","key":"1003_CR195","doi-asserted-by":"publisher","first-page":"e7475","DOI":"10.1371\/journal.pone.0007475","volume":"4","author":"D Pilling","year":"2009","unstructured":"Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE. 2009;4(10):e7475.","journal-title":"PLoS ONE"},{"issue":"4","key":"1003_CR196","doi-asserted-by":"publisher","first-page":"e70166","DOI":"10.1002\/jcp.70166","volume":"241","author":"S Kato","year":"2026","unstructured":"Kato S, Kawamura T, Maekawa T, Ogata H, Tachi N, Osawa Y, et al. Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement. J Cell Physiol. 2026;241(4):e70166.","journal-title":"J Cell Physiol"},{"issue":"8","key":"1003_CR197","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","volume":"126","author":"M Lu","year":"2015","unstructured":"Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D, et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood. 2015;126(8):972\u201382.","journal-title":"Blood"},{"issue":"2","key":"1003_CR198","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","volume":"13","author":"AO Khan","year":"2023","unstructured":"Khan AO, Rodriguez-Romera A, Reyat JS, Olijnik AA, Colombo M, Wang G, et al. Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies. Cancer Discov. 2023;13(2):364\u201385.","journal-title":"Cancer Discov"},{"issue":"10","key":"1003_CR199","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.3324\/haematol.2024.287231","volume":"110","author":"P Vachhani","year":"2025","unstructured":"Vachhani P, Tan P, Watson AM, Wu SJ, Baker R, Cheung S, et al. A phase I\/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis. Haematologica. 2025;110(10):2376\u201387.","journal-title":"Haematologica"},{"issue":"12","key":"1003_CR200","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/blood-2004-01-0193","volume":"104","author":"L Centurione","year":"2004","unstructured":"Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood. 2004;104(12):3573\u201380.","journal-title":"Blood"},{"issue":"8","key":"1003_CR201","doi-asserted-by":"publisher","first-page":"qiaf093","DOI":"10.1093\/jleuko\/qiaf093","volume":"117","author":"RJ Collinson","year":"2025","unstructured":"Collinson RJ, Linden MD, Fuller KA, Wilson L, Mirzai B, Boey D, et al. Megakaryocyte emperipolesis in myeloproliferative neoplasms: Are neutrophils friends or foes? J Leukoc Biol. 2025;117(8):qiaf093.","journal-title":"J Leukoc Biol"},{"key":"1003_CR202","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exphem.2023.02.003","volume":"121","author":"F Arciprete","year":"2023","unstructured":"Arciprete F, Verachi P, Martelli F, Valeri M, Balliu M, Guglielmelli P, et al. Inhibition of CXCR1\/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1(low) model of myelofibrosis. Exp Hematol. 2023;121:30\u20137.","journal-title":"Exp Hematol"},{"issue":"6","key":"1003_CR203","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/blood.2024027455","volume":"146","author":"E Khatib-Massalha","year":"2025","unstructured":"Khatib-Massalha E, Di Buduo CA, Chedeville AL, Ho YH, Zhu Y, Grockowiak E, et al. Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24. Blood. 2025;146(6):717\u201331.","journal-title":"Blood"},{"issue":"4","key":"1003_CR204","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.4081\/ejh.2025.4427","volume":"69","author":"F Arciprete","year":"2025","unstructured":"Arciprete F, Velardi V, Di Virgilio A, Verachi P, Carta C, Pozzi G, et al. Genetic deletion of P-selectin prevents fibrosis development by inhibiting the neutrophil megakaryocyte emperipolesis in the Gata1(low) mouse model for myelofibrosis. Eur J Histochem. 2025;69(4):4427.","journal-title":"Eur J Histochem"},{"issue":"9","key":"1003_CR205","doi-asserted-by":"publisher","first-page":"e0222912","DOI":"10.1371\/journal.pone.0222912","volume":"14","author":"T Manshouri","year":"2019","unstructured":"Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, et al. Primary myelofibrosis marrow-derived CD14+\/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS ONE. 2019;14(9):e0222912.","journal-title":"PLoS ONE"},{"issue":"9","key":"1003_CR206","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.2025028703","volume":"147","author":"Y Yan","year":"2026","unstructured":"Yan Y, Liu J, Zhao S, Li F, Yang L, Xu Z, et al. The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms. Blood. 2026;147(9):946\u201359.","journal-title":"Blood"},{"issue":"1","key":"1003_CR207","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cjp2.240","volume":"8","author":"SH Lee","year":"2022","unstructured":"Lee SH, Lin CC, Wei CH, Chang KP, Yuan CT, Tsai CH, et al. PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. J Pathol Clin Res. 2022;8(1):78\u201387.","journal-title":"J Pathol Clin Res"},{"key":"1003_CR208","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-031-26163-3_15","volume":"1408","author":"S Kapor","year":"2023","unstructured":"Kapor S, Momcilovic S, Kapor S, Mojsilovic S, Radojkovic M, Apostolovic M, et al. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis. Adv Exp Med Biol. 2023;1408:273\u201390.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"1003_CR209","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1038\/s41375-025-02706-3","volume":"39","author":"M Bauer","year":"2025","unstructured":"Bauer M, Vaxevanis C, Jaekel N, Hackl H, Wilfer A, Zoellig C, et al. Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-gamma signaling and driver mutations. Leukemia. 2025;39(10):2391\u2013405.","journal-title":"Leukemia"},{"key":"1003_CR210","doi-asserted-by":"publisher","first-page":"1809031","DOI":"10.3389\/fcell.2026.1809031","volume":"14","author":"R Campanelli","year":"2026","unstructured":"Campanelli R, Mantovani S, Ramirez C, Tebaldi T, La Gaipa A, Del Fante C, et al. Understanding the link between PMN-MDSCs and CXCL8-CXCR1\/2 axis in primary myelofibrosis. Front Cell Dev Biol. 2026;14:1809031.","journal-title":"Front Cell Dev Biol"},{"key":"1003_CR211","doi-asserted-by":"publisher","unstructured":"He F, Lin S, Kong T, Fisher DAC, Kim AB, Ramesh V, et al. Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032631.","DOI":"10.1182\/blood.2025032631"},{"issue":"17","key":"1003_CR212","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.3390\/jcm14176328","volume":"14","author":"SB Todor","year":"2025","unstructured":"Todor SB, Mihaila RG. Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review. J Clin Med. 2025;14(17):6328.","journal-title":"J Clin Med"},{"issue":"3","key":"1003_CR213","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316\u201331.","journal-title":"Cancer Discov"},{"issue":"1","key":"1003_CR214","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018;33(1):29\u201343. e7.","journal-title":"Cancer Cell"},{"issue":"3","key":"1003_CR215","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1084\/jem.20181074","volume":"216","author":"A Malara","year":"2019","unstructured":"Malara A, Gruppi C, Abbonante V, Cattaneo D, De Marco L, Massa M, et al. EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. J Exp Med. 2019;216(3):587\u2013604.","journal-title":"J Exp Med"},{"issue":"10","key":"1003_CR216","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/leu.2013.74","volume":"27","author":"T Barbui","year":"2013","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27(10):1953\u20138.","journal-title":"Leukemia"},{"issue":"11","key":"1003_CR217","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","volume":"8","author":"G Finazzi","year":"2018","unstructured":"Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J. 2018;8(11):104.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1003_CR218","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajh.24788","volume":"92","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B, Wolfler A, Schalling M, Gleiss A, et al. Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92(9):885\u201391.","journal-title":"Am J Hematol"},{"issue":"8","key":"1003_CR219","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128\u201332.","journal-title":"Haematologica"},{"issue":"21","key":"1003_CR220","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117(21):5710\u20138.","journal-title":"Blood"},{"issue":"60","key":"1003_CR221","doi-asserted-by":"publisher","first-page":"101735","DOI":"10.18632\/oncotarget.21594","volume":"8","author":"E Rumi","year":"2017","unstructured":"Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant\u2019Antonio E, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017;8(60):101735\u201344.","journal-title":"Oncotarget"},{"issue":"3","key":"1003_CR222","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","volume":"97","author":"T Buhr","year":"2012","unstructured":"Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360\u20135.","journal-title":"Haematologica"},{"issue":"5","key":"1003_CR223","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.clml.2014.11.002","volume":"15","author":"O Pozdnyakova","year":"2015","unstructured":"Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2015;15(5):253\u201361.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"1003_CR224","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/bloodadvances.2020002230","volume":"4","author":"K Sirinukunwattana","year":"2020","unstructured":"Sirinukunwattana K, Aberdeen A, Theissen H, Sousos N, Psaila B, Mead AJ, et al. Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients. Blood Adv. 2020;4(14):3284\u201394.","journal-title":"Blood Adv"},{"issue":"2","key":"1003_CR225","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41375-022-01773-0","volume":"37","author":"H Ryou","year":"2023","unstructured":"Ryou H, Sirinukunwattana K, Aberdeen A, Grindstaff G, Stolz BJ, Byrne H, et al. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients. Leukemia. 2023;37(2):348\u201358.","journal-title":"Leukemia"},{"issue":"2","key":"1003_CR226","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00428-025-04122-5","volume":"489","author":"G D\u2019Abbronzo","year":"2026","unstructured":"D\u2019Abbronzo G, D\u2019Antonio A, De Chiara A, Panico L, Sparano L, Diluvio A, et al. Development of an automated artificial intelligence-based tool for reticulin fibrosis assessment in bone marrow biopsies. Virchows Arch. 2026;489(2):495\u2013502.","journal-title":"Virchows Arch"},{"issue":"1","key":"1003_CR227","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41597-025-06450-2","volume":"13","author":"L Zhuang","year":"2026","unstructured":"Zhuang L, Zhang Y, Zhao X, Zhao H, Li P, Jiang Z. An open bone marrow megakaryocyte dataset for automated morphologic studies. Sci Data. 2026;13(1):134.","journal-title":"Sci Data"},{"issue":"5","key":"1003_CR228","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41375-026-02893-7","volume":"40","author":"A Srisuwananukorn","year":"2026","unstructured":"Srisuwananukorn A, Loscocco GG, Dolezal JM, Kuykendall AT, Santi R, Zhang L, et al. Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images. Leukemia. 2026;40(5):1018\u201326.","journal-title":"Leukemia"},{"issue":"7","key":"1003_CR229","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.leukres.2010.01.005","volume":"34","author":"CJ Teman","year":"2010","unstructured":"Teman CJ, Wilson AR, Perkins SL, Hickman K, Prchal JT, Salama ME. Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study. Leuk Res. 2010;34(7):871\u20136.","journal-title":"Leuk Res"},{"issue":"4","key":"1003_CR230","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.14440\/jbm.2016.152","volume":"3","author":"HA Lucero","year":"2016","unstructured":"Lucero HA, Patterson S, Matsuura S, Ravid K. Quantitative histological image analyses of reticulin fibers in a myelofibrotic mouse. J Biol Methods. 2016;3(4):e60.","journal-title":"J Biol Methods"},{"issue":"6","key":"1003_CR231","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1002\/hem3.105","volume":"8","author":"H Ryou","year":"2024","unstructured":"Ryou H, Sirinukunwattana K, Wood R, Aberdeen A, Rittscher J, Weinberg OK, et al. Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa. Hemasphere. 2024;8(6):e105.","journal-title":"Hemasphere"},{"issue":"4","key":"1003_CR232","doi-asserted-by":"publisher","first-page":"e70269","DOI":"10.1002\/jbio.70269","volume":"19","author":"X Yu","year":"2026","unstructured":"Yu X, Guo G, Zhang X, Chen X, Huang X, Li L. Second Harmonic Generation-Based Collagen Analysis and Automated Grading of Myelofibrosis. J Biophotonics. 2026;19(4):e70269.","journal-title":"J Biophotonics"},{"issue":"9","key":"1003_CR233","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","volume":"25","author":"U Gianelli","year":"2012","unstructured":"Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25(9):1193\u2013202.","journal-title":"Mod Pathol"},{"issue":"6","key":"1003_CR234","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3324\/haematol.2015.141283","volume":"101","author":"AA Zahr","year":"2016","unstructured":"Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101(6):660\u201371.","journal-title":"Haematologica"},{"issue":"9","key":"1003_CR235","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.24442","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918\u201322.","journal-title":"Am J Hematol"},{"issue":"4","key":"1003_CR236","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018;36(4):310\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1003_CR237","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/his.13309","volume":"71","author":"U Gianelli","year":"2017","unstructured":"Gianelli U, Fiori S, Cattaneo D, Bossi A, Cortinovis I, Bonometti A, et al. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. Histopathology. 2017;71(6):897\u2013908.","journal-title":"Histopathology"},{"issue":"9","key":"1003_CR238","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/PAI.0000000000000000","volume":"22","author":"N Sangle","year":"2014","unstructured":"Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, et al. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. Appl Immunohistochem Mol Morphol. 2014;22(9):663\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"1003_CR239","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"1003_CR240","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3343\/alm.2018.38.4.296","volume":"38","author":"N Yang","year":"2018","unstructured":"Yang N, Park S, Cho MS, Lee M, Hong KS, Mun YC, et al. GATA1 Expression in BCR\/ABL1-negative Myeloproliferative Neoplasms. Ann Lab Med. 2018;38(4):296\u2013305.","journal-title":"Ann Lab Med"},{"key":"1003_CR241","doi-asserted-by":"publisher","first-page":"106495","DOI":"10.1016\/j.leukres.2020.106495","volume":"100","author":"VFI Sangiorgio","year":"2021","unstructured":"Sangiorgio VFI, Nam A, Chen Z, Orazi A, Tam W. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leuk Res. 2021;100:106495.","journal-title":"Leuk Res"},{"issue":"2","key":"1003_CR242","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/biom12020234","volume":"12","author":"M Zingariello","year":"2022","unstructured":"Zingariello M, Verachi P, Gobbo F, Martelli F, Falchi M, Mazzarini M, et al. Resident Self-Tissue of Proinflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Gata1(low) Mice. Biomolecules. 2022;12(2):234.","journal-title":"Biomolecules"},{"issue":"6","key":"1003_CR243","doi-asserted-by":"publisher","first-page":"e240501","DOI":"10.1148\/rycan.240501","volume":"7","author":"TH Robison","year":"2025","unstructured":"Robison TH, Levinson A, Lee W, Pettit K, Malyarenko D, Kandarpa M, et al. Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study. Radiol Imaging Cancer. 2025;7(6):e240501.","journal-title":"Radiol Imaging Cancer"},{"issue":"1","key":"1003_CR244","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Zehtabcheh S, Seraji HR, Beqaj SH, Tayefeh S, Mohammadi MH, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"3","key":"1003_CR245","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ijlh.12787","volume":"40","author":"LL Herborg","year":"2018","unstructured":"Herborg LL, Nederby L, Hasselbalch HC, Aggerholm A, Roug AS. Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. Int J Lab Hematol. 2018;40(3):320\u20135.","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"1003_CR246","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395\u20138.","journal-title":"Blood"},{"issue":"1","key":"1003_CR247","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjh.19186","volume":"204","author":"DP McLornan","year":"2024","unstructured":"McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, et al. The management of myelofibrosis: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):136\u201350.","journal-title":"Br J Haematol"},{"issue":"9","key":"1003_CR248","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"issue":"9","key":"1003_CR249","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"5","key":"1003_CR250","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015;1(5):643\u201351.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1003_CR251","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225\u201336.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1003_CR252","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018;4(5):652\u20139.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1003_CR253","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.17727","volume":"195","author":"A Pardanani","year":"2021","unstructured":"Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol. 2021;195(2):244\u20138.","journal-title":"Br J Haematol"},{"issue":"10373","key":"1003_CR254","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269\u201380.","journal-title":"Lancet"},{"issue":"12","key":"1003_CR255","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/ajh.26709","volume":"97","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, et al. Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial. Am J Hematol. 2022;97(12):1510\u20139.","journal-title":"Am J Hematol"},{"issue":"10","key":"1003_CR256","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/ajh.27031","volume":"98","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang Q, Liu Q, Dang H, Gao S, Wang W, et al. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023;98(10):1579\u201387.","journal-title":"Am J Hematol"},{"issue":"10","key":"1003_CR257","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/ajh.27033","volume":"98","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, et al. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023;98(10):1588\u201397.","journal-title":"Am J Hematol"},{"issue":"4","key":"1003_CR258","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/ajh.27245","volume":"99","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, et al. Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100\u00a0mg twice daily (BID) and 200\u00a0mg once daily (QD) in patients with myelofibrosis. Am J Hematol. 2024;99(4):774\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"1003_CR259","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41408-024-01202-8","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhou H, Suo S, Zhuang J, Yang L, He A, et al. Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study. Blood Cancer J. 2024;14(1):216.","journal-title":"Blood Cancer J"},{"key":"1003_CR260","doi-asserted-by":"publisher","first-page":"178032","DOI":"10.1016\/j.ejphar.2025.178032","volume":"1005","author":"M Hong","year":"2025","unstructured":"Hong M, Ding D, Zhang M, Gao S, Song L, Wu D, et al. A first-in-class JAK\/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study. Eur J Pharmacol. 2025;1005:178032.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1003_CR261","first-page":"1393","volume":"86","author":"HA Blair","year":"2026","unstructured":"Blair HA, Rovadicitinib. First Approval Drugs. 2026;86(8):1393\u20139.","journal-title":"First Approval Drugs"},{"issue":"1","key":"1003_CR262","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","volume":"11","author":"HM Kvasnicka","year":"2018","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018;11(1):42.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1003_CR263","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","volume":"34","author":"RJ Austin","year":"2020","unstructured":"Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, et al. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia. 2020;34(4):1075\u201389.","journal-title":"Leukemia"},{"issue":"5","key":"1003_CR264","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2159-8290.CD-22-0952","volume":"14","author":"AJ Dunbar","year":"2024","unstructured":"Dunbar AJ, Bowman RL, Park YC, O\u2019Connor K, Izzo F, Myers RM, et al. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer Discov. 2024;14(5):737\u201351.","journal-title":"Cancer Discov"},{"issue":"19","key":"1003_CR265","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1182\/blood-2014-02-558015","volume":"124","author":"X Wang","year":"2014","unstructured":"Wang X, Ye F, Tripodi J, Hu CS, Qiu J, Najfeld V, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 2014;124(19):2987\u201395.","journal-title":"Blood"},{"issue":"3","key":"1003_CR266","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bjh.18526","volume":"200","author":"A Iurlo","year":"2023","unstructured":"Iurlo A, Galli N, Bucelli C, Artuso S, Consonni D, Cattaneo D. Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment. Br J Haematol. 2023;200(3):315\u201322.","journal-title":"Br J Haematol"},{"issue":"1","key":"1003_CR267","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","volume":"11","author":"E Mylonas","year":"2020","unstructured":"Mylonas E, Yoshida K, Frick M, Hoyer K, Christen F, Kaeda J, et al. Single-cell analysis based dissection of clonality in myelofibrosis. Nat Commun. 2020;11(1):73.","journal-title":"Nat Commun"},{"issue":"1","key":"1003_CR268","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1038\/s41467-025-60884-1","volume":"16","author":"N Maslah","year":"2025","unstructured":"Maslah N, Kaci N, Roux B, Alexe G, Marie R, Pasquer H, et al. JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. Nat Commun. 2025;16(1):6270.","journal-title":"Nat Commun"},{"issue":"6","key":"1003_CR269","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1038\/bcj.2017.51","volume":"7","author":"M Zingariello","year":"2017","unstructured":"Zingariello M, Sancillo L, Martelli F, Ciaffoni F, Marra M, Varricchio L, et al. The thrombopoietin\/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J. 2017;7(6):e572.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1003_CR270","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s40364-025-00865-0","volume":"13","author":"G Coltro","year":"2025","unstructured":"Coltro G, Videschi V, Gesullo F, Violi F, Balliu M, Vannucchi AM, et al. Combinatorial BCL2\/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis. Biomark Res. 2025;13(1):151.","journal-title":"Biomark Res"},{"issue":"18","key":"1003_CR271","doi-asserted-by":"publisher","first-page":"e145651","DOI":"10.1172\/jci.insight.145651","volume":"6","author":"L Varricchio","year":"2021","unstructured":"Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, et al. TGF-beta1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight. 2021;6(18):e145651.","journal-title":"JCI Insight"},{"issue":"18","key":"1003_CR272","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1158\/1078-0432.CCR-23-0276","volume":"29","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas J, Migliaccio AR, Kosiorek H, Bhave R, Palmer J, Kuykendall A, et al. A Phase Ib Trial of AVID200, a TGFbeta 1\/3 Trap, in Patients with Myelofibrosis. Clin Cancer Res. 2023;29(18):3622\u201332.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1003_CR273","doi-asserted-by":"publisher","first-page":"a027987","DOI":"10.1101\/cshperspect.a027987","volume":"9","author":"K Naka","year":"2017","unstructured":"Naka K, Hirao A. Regulation of Hematopoiesis and Hematological Disease by TGF-beta Family Signaling Molecules. Cold Spring Harb Perspect Biol. 2017;9(9):a027987.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"12","key":"1003_CR274","doi-asserted-by":"publisher","first-page":"a022277","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane J, Gomis RR. TGF-beta Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harb Perspect Biol. 2017;9(12):a022277.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"19","key":"1003_CR275","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massague","year":"2023","unstructured":"Massague J, Sheppard D. TGF-beta signaling in health and disease. Cell. 2023;186(19):4007\u201337.","journal-title":"Cell"},{"key":"1003_CR276","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2025-483","volume":"146","author":"A Kuykendall","year":"2025","unstructured":"Kuykendall A, Roy R, Yacoub A, Kremyanskaya M, Gerds A, Paquette R, et al. A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1. Blood. 2025;146:483.","journal-title":"Blood"},{"issue":"16","key":"1003_CR277","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2025015860","volume":"9","author":"DM Ross","year":"2025","unstructured":"Ross DM, Heidel FH, Perkins AC, Reiter A, Crodel C, Riley C, et al. ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis. Blood Adv. 2025;9(16):4195\u2013205.","journal-title":"Blood Adv"},{"issue":"23","key":"1003_CR278","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","volume":"5","author":"G Hobbs","year":"2021","unstructured":"Hobbs G, Cimen Bozkus C, Moshier E, Dougherty M, Bar-Natan M, Sandy L, et al. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021;5(23):5086\u201397.","journal-title":"Blood Adv"},{"key":"1003_CR279","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.leukres.2019.02.012","volume":"79","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, et al. Phase 1\/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leuk Res. 2019;79:38\u201344.","journal-title":"Leuk Res"},{"issue":"13","key":"1003_CR280","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/bloodadvances.2019001212","volume":"4","author":"V Gupta","year":"2020","unstructured":"Gupta V, Wolleschak D, Hasselbalch H, Vannucchi AM, Koschmieder S, Cervantes F, et al. Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b\/2 dose-finding study. Blood Adv. 2020;4(13):3063\u201371.","journal-title":"Blood Adv"},{"issue":"1","key":"1003_CR281","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kroger","year":"2024","unstructured":"Kroger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11(1):e62\u201374.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1003_CR282","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ajh.27274","volume":"99","author":"H Ali","year":"2024","unstructured":"Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. Am J Hematol. 2024;99(5):938\u201345.","journal-title":"Am J Hematol"},{"issue":"2","key":"1003_CR283","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa2408941","volume":"392","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Luck C, et al. Clearance of Driver Mutations after Transplantation for Myelofibrosis. N Engl J Med. 2025;392(2):150\u201360.","journal-title":"N Engl J Med"},{"issue":"22","key":"1003_CR284","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood.2024024373","volume":"144","author":"ES Reis","year":"2024","unstructured":"Reis ES, Buonpane R, Celik H, Marty C, Lei A, Jobe F, et al. Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN. Blood. 2024;144(22):2336\u201348.","journal-title":"Blood"},{"key":"1003_CR285","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/blood-2025-484","volume":"146","author":"J Mascarenhas","year":"2025","unstructured":"Mascarenhas J, Al-Ali HK, Gupta V, Ali H, Palandri F, Passamonti PF, et al. Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies. Blood. 2025;146:484.","journal-title":"Blood"},{"key":"1003_CR286","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2025-71","volume":"146","author":"B Psaila","year":"2025","unstructured":"Psaila B, Nangalia J, Gotlib J, Harrison C, Mascarenhas J, Crowgey E, et al. Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells. Blood. 2025;146:71.","journal-title":"Blood"},{"issue":"4","key":"1003_CR287","doi-asserted-by":"publisher","first-page":"e52904","DOI":"10.15252\/embr.202152904","volume":"23","author":"D Tvorogov","year":"2022","unstructured":"Tvorogov D, Thompson-Peach CAL, Fosselteder J, Dottore M, Stomski F, Onnesha SA, et al. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. EMBO Rep. 2022;23(4):e52904.","journal-title":"EMBO Rep"},{"key":"1003_CR288","doi-asserted-by":"publisher","first-page":"1240678","DOI":"10.3389\/fimmu.2023.1240678","volume":"14","author":"MO Holmstrom","year":"2023","unstructured":"Holmstrom MO, Andersen M, Traynor S, Ahmad SM, Lisle TL, Handlos Grauslund J, et al. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow. Front Immunol. 2023;14:1240678.","journal-title":"Front Immunol"},{"issue":"14","key":"1003_CR289","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1182\/blood.2024027897","volume":"147","author":"CAL Thompson-Peach","year":"2026","unstructured":"Thompson-Peach CAL, Thomas D, Dottore M, Lim K, Stomski F, Panagopoulos RA, et al. Ultraprecision therapy for type 1 vs type 2 CALR\u2009+\u2009MPN by dual epitope targeting that restores ruxolitinib sensitivity. Blood. 2026;147(14):1611\u201323.","journal-title":"Blood"},{"issue":"856","key":"1003_CR290","doi-asserted-by":"publisher","first-page":"eadz3553","DOI":"10.1126\/scitranslmed.adz3553","volume":"18","author":"A Rampotas","year":"2026","unstructured":"Rampotas A, Wong ZC, Gannon I, Brierley CK, Shen Y, Benlabiod C, et al. CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis. Sci Transl Med. 2026;18(856):eadz3553.","journal-title":"Sci Transl Med"},{"issue":"12","key":"1003_CR291","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3995","volume":"21","author":"QJ Wen","year":"2015","unstructured":"Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015;21(12):1473\u201380.","journal-title":"Nat Med"},{"issue":"16","key":"1003_CR292","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","volume":"25","author":"N Gangat","year":"2019","unstructured":"Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, et al. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019;25(16):4898\u2013906.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1003_CR293","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069\u201376.","journal-title":"Blood"},{"issue":"12","key":"1003_CR294","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.3324\/haematol.2018.209965","volume":"104","author":"ST Durrant","year":"2019","unstructured":"Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104(12):e551\u20134.","journal-title":"Haematologica"},{"issue":"6","key":"1003_CR295","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/bloodadvances.2023011620","volume":"8","author":"A Yacoub","year":"2024","unstructured":"Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, et al. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024;8(6):1515\u201328.","journal-title":"Blood Adv"},{"issue":"7","key":"1003_CR296","doi-asserted-by":"publisher","first-page":"oyag201","DOI":"10.1093\/oncolo\/oyag201","volume":"31","author":"JJ Kiladjian","year":"2026","unstructured":"Kiladjian JJ, Borate U, Abruzzese E, De Stefano V, Gong T, Breccia M, et al. Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. Oncologist. 2026;31(7):oyag201.","journal-title":"Oncologist"},{"issue":"26","key":"1003_CR297","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.20.02864","volume":"39","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, et al. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021;39(26):2881\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1003_CR298","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00277-021-04683-w","volume":"101","author":"AT Kuykendall","year":"2022","unstructured":"Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, et al. Favorable overall survival with imetelstat in relapsed\/refractory myelofibrosis patients compared with real-world data. Ann Hematol. 2022;101(1):139\u201346.","journal-title":"Ann Hematol"},{"issue":"22","key":"1003_CR299","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2217\/fon-2022-0235","volume":"18","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Harrison CN, Kiladjian JJ, Komrokji RS, Koschmieder S, Vannucchi AM, et al. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol. 2022;18(22):2393\u2013402.","journal-title":"Future Oncol"},{"issue":"13","key":"1003_CR300","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1182\/bloodadvances.2025018141","volume":"10","author":"H Gill","year":"2026","unstructured":"Gill H, Yacoub A, Gerds AT, Shortt J, Rossetti JM, Mead AJ, et al. The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1\/2 study. Blood Adv. 2026;10(13):4585\u201394.","journal-title":"Blood Adv"},{"issue":"11","key":"1003_CR301","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1182\/bloodadvances.2026019612","volume":"10","author":"H Gill","year":"2026","unstructured":"Gill H, Au L, Yim R, Lee P, Li V, Chin L, et al. Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction. Blood Adv. 2026;10(11):3920\u201330.","journal-title":"Blood Adv"},{"issue":"4","key":"1003_CR302","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41375-026-02871-z","volume":"40","author":"X Wang","year":"2026","unstructured":"Wang X, Davis A, Hu CS, Huang F, Jiang S, Mascarenhas J, et al. Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells. Leukemia. 2026;40(4):827\u201331.","journal-title":"Leukemia"},{"issue":"6","key":"1003_CR303","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","volume":"20","author":"N Kroger","year":"2014","unstructured":"Kroger N, Zabelina T, Alchalby H, Stubig T, Wolschke C, Ayuk F, et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2014;20(6):812\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"1003_CR304","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","volume":"31","author":"RK Rampal","year":"2025","unstructured":"Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31(5):1531\u20138.","journal-title":"Nat Med"},{"issue":"22","key":"1003_CR305","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO-26-01080","volume":"44","author":"P Bose","year":"2026","unstructured":"Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, et al. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naive Myelofibrosis: Phase III SENTRY Trial. J Clin Oncol. 2026;44(22):2098\u2013109.","journal-title":"J Clin Oncol"},{"key":"1003_CR306","doi-asserted-by":"publisher","unstructured":"Pemmaraju N, Mead AJ, Somervaille TCP, Palandri F, Koschmieder S, Delage R, et al. TRANSFORM-1 Phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032360.","DOI":"10.1182\/blood.2025032360"},{"issue":"2","key":"1003_CR307","doi-asserted-by":"publisher","first-page":"e70273","DOI":"10.1002\/jha2.70273","volume":"7","author":"T Kawamura","year":"2026","unstructured":"Kawamura T, Maekawa T, Kouzu K, Ogata H, Tachi N, Kato S, et al. Sequential Analysis of Murine Myelofibrosis Models Using a Novel Deep Learning-Based Fibrosis Quantitative Method. EJHaem. 2026;7(2):e70273.","journal-title":"EJHaem"},{"key":"1003_CR308","doi-asserted-by":"publisher","first-page":"720552","DOI":"10.3389\/fgene.2021.720552","volume":"12","author":"F Martelli","year":"2021","unstructured":"Martelli F, Verachi P, Zingariello M, Mazzarini M, Vannucchi AM, Lonetti A, et al. hGATA1 Under the Control of a muLCR\/beta-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1 (low) Mutation in Mice. Front Genet. 2021;12:720552.","journal-title":"Front Genet"},{"issue":"2","key":"1003_CR309","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.V88.2.402.bloodjournal882402","volume":"88","author":"XQ Yan","year":"1996","unstructured":"Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88(2):402\u20139.","journal-title":"Blood"},{"issue":"6","key":"1003_CR310","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584\u201396.","journal-title":"Cancer Cell"},{"issue":"1","key":"1003_CR311","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40364-024-00641-6","volume":"12","author":"Q Wei","year":"2024","unstructured":"Wei Q, Gan C, Sun M, Xie Y, Liu H, Xue T, et al. BRD4: an effective target for organ fibrosis. Biomark Res. 2024;12(1):92.","journal-title":"Biomark Res"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01003-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:03:01Z","timestamp":1790744581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-01003-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":311,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01003-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"128"}}